BioMarin Pharmaceutical | BMRN - Assets

Stock Price
64.08
Daily Change
0.66 1.04%
Monthly
12.88%
Yearly
-6.11%
Q1 Forecast
62.09

BioMarin Pharmaceutical reported $7.61B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Bayer EUR 104.21B 1.03B Sep/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
United Therapeutics USD 7.35B 556.9M Sep/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025